HealthcareNasdaqsmall
Institutional-grade research for retail investors
SEC EDGAR: CIK 1997296MDCX stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

MDCX Stock Analysis & AI Quality Score

Data updated 2026-07-26

AI stock analysis and institutional research for Medicus Pharma Ltd. (MDCX), a Healthcare sector company. MDCX is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of MDCX by reported 13-F value include Interchange Capital Partners, JANE STREET GROUP, XTX Topco Ltd, based on the most recent SEC filings. MDCX trades on the Nasdaq exchange and files with the SEC under CIK 1997296. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MDCX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Medicus Pharma Ltd. directly from SEC EDGAR.

Net Income

Q2 2026

$-11.6M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Net Income

-323.8% YoY
$-47.3MFY 2025
FY22 FY23 $-5.3MFY24 $-11.2MFY25 $-47.3M

Operating Income

-207.3% YoY
$-34.4MFY 2025
FY22 FY23 $-4.7MFY24 $-11.2MFY25 $-34.4M

EPS (Diluted)

-136.2% YoY
$-2.74FY 2025
FY22 FY23 $-1.53FY24 $-1.16FY25 $-2.74

Total Assets

+78.2% YoY
$10.1MFY 2025
FY22 FY23 $1.9MFY24 $5.6MFY25 $10.1M

Total Debt

$5.2MFY 2025
FY22 FY23 FY24 $0.00FY25 $5.2M

Op. Cash Flow

-122.3% YoY
$-22.8MFY 2025
FY22 FY23 $-4.2MFY24 $-10.2MFY25 $-22.8M

Get alerted when MDCX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Medicus Pharma Ltd. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Put MDCX on your watchlist

Track score changes the day Medicus Pharma Ltd. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is MDCX a good stock to buy?

13F Pro's AI-powered analysis of Medicus Pharma Ltd. (MDCX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MDCX are available on the MDCX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. MDCX is classified as a small company.

Which hedge funds own MDCX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MDCX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Medicus Pharma Ltd.'s investment landscape.